Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases
Histone deacetylases (HDACs) are enzymes that play an essential role in the onset and progression of cancer. As a consequence, a variety of HDAC inhibitors (HDACis) have been developed as potent anticancer agents, several of which have been approved by the FDA for cancer treatment. However, recent a...
Saved in:
| Main Authors: | Maria A. Theodoropoulou, Christiana Mantzourani, George Kokotos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1605 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
by: Antonio Curcio, et al.
Published: (2024-05-01) -
Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitor
by: Ilaria Cursaro, et al.
Published: (2025-08-01) -
Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications
by: Zhiyi Wang, et al.
Published: (2025-06-01) -
Butyrate inhibits histone deacetylase 2 expression to alleviate liver fibrosis in biliary atresia
by: Yilin Zhao, et al.
Published: (2025-04-01) -
Antiplasmodial activity of pentyloxyamide-based histone deacetylase inhibitors against Plasmodium falciparum parasites
by: Wisam A. Dawood, et al.
Published: (2025-12-01)